Compare Duke Energy Corp (DUK) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Summit Therapeutics Inc — how do they compare? Duke Energy Corp trades at $116.65 (market cap $91.10B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Duke Energy Corp is far larger — about 6.6× Summit Therapeutics Inc's market cap, and Duke Energy Corp pays a 3.71% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Summit Therapeutics Inc for 16 Days on average.
| DUK | SMMT | |
|---|---|---|
Market Cap | $91.10B | $13.71B |
Volume | 4,199,050 | 6,173,057 |
Sector | Utilities | Health |
52-Week High | $133.46 | $26.38 |
52-Week Low | $113.23 | $12.43 |
Typical Hold Time | 74 Days | 16 Days |
Enterprise Value | $183.61B | $13.04B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.84, up 1.16% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals with a P/E of 17.6, net income margin of 15.78%, and robust cash flow from operations of $12.33B in 2025. Recent news highlights dividend declarations and data center growth opportunities, while analyst consensus is mixed with a $134.44 price target.
DUK offers a stable investment with reliable dividends and growth from data center demand, but faces risks from rising Treasury yields, high debt levels, and regulatory pressures. The stock's valuation is reasonable, and institutional interest remains positive, though technical indicators suggest near-term resistance at $118.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
